Roth Capital Forecasts Electromed's Q1 Earnings (NYSE:ELMD)

Key Points

• Roth Capital has revised its Q1 2026 earnings forecast for Electromed, now estimating $0.20 per share instead of $0.22, while maintaining a "Buy" rating and a target price of $35.00.
• Electromed stock has risen 19.9%, opening at $24.77, and is currently seeing significant interest from hedge funds, with over 40% of shares owned by institutional investors.
• Multiple research analysts have varying ratings for Electromed, with the overall consensus being an average "Buy" rating and a price target of $36.25.

Electromed, Inc. (NYSE:ELMD - Free Report) - Research analysts at Roth Capital cut their Q1 2026 earnings estimates for Electromed in a research report issued to clients and investors on Wednesday, August 27th. Roth Capital analyst K. Bauser now anticipates that the company will earn $0.20 per share for the quarter, down from their previous estimate of $0.22. Roth Capital currently has a "Buy" rating and a $35.00 target price on the stock. Roth Capital also issued estimates for Electromed's Q2 2026 earnings at $0.27 EPS, Q3 2026 earnings at $0.23 EPS, Q4 2026 earnings at $0.34 EPS, FY2026 earnings at $1.04 EPS and FY2027 earnings at $1.23 EPS.

Other equities research analysts have also issued research reports about the stock. Lake Street Capital initiated coverage on shares of Electromed in a research note on Wednesday. They issued a "buy" rating and a $36.00 price target on the stock. Wall Street Zen lowered Electromed from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 8th. Loop Capital set a $36.00 target price on Electromed in a research report on Wednesday. Finally, B. Riley raised Electromed to a "strong-buy" rating in a research note on Thursday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company's stock. According to MarketBeat.com, Electromed has an average rating of "Buy" and an average price target of $36.25.

Electromed Stock Up 19.9%

Electromed stock opened at $24.77 on Thursday. The firm has a 50-day moving average price of $19.73 and a two-hundred day moving average price of $22.27. The firm has a market capitalization of $207.72 million, a price-to-earnings ratio of 33.03 and a beta of 0.38. Electromed has a 52-week low of $13.74 and a 52-week high of $35.56.

Hedge Funds Weigh In On Electromed

Several hedge funds have recently modified their holdings of ELMD. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Electromed in the 2nd quarter worth $32,000. State of Wyoming acquired a new position in Electromed during the first quarter worth about $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Electromed during the second quarter worth about $83,000. New York State Common Retirement Fund bought a new stake in Electromed in the second quarter worth about $103,000. Finally, Bank of America Corp DE lifted its holdings in Electromed by 179.2% in the 4th quarter. Bank of America Corp DE now owns 4,004 shares of the company's stock valued at $118,000 after acquiring an additional 2,570 shares during the last quarter. 40.82% of the stock is currently owned by institutional investors and hedge funds.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.